BCX7353: Phase II started

BioCryst began the double-blind, placebo-controlled, international Phase II ApeX-1 trial of oral BCX7353 in up to 50 patients. The first part of ApeX-1 will evaluate once-daily 350 mg BCX7353 for 28 d...